Dian Diagnostics Group Co.,Ltd.

300244

CNE1000015N1

Healthcare Facilities & Services

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-04-14 pm EDT			5-day change	1st Jan Change
14.99 ^CNY	+0.33%		-6.14%	-37.04%

Feb. 06	Dian Diagnostics Group Co.,Ltd. announces an Equity Buyback for CNY 200 million worth of its shares.	CI
Feb. 06	Dian Diagnostics Group Co.,Ltd. authorizes a Buyback Plan.	CI

Dian Diagnostics Group Co.,Ltd. Proposes Final Cash Dividend for 2020

April 12, 2021 at 03:39 pm EDT

Dian Diagnostics Group Co.,Ltd. proposed final cash dividend of CNY 1.30000000 per 10 shares (tax included) for 2020.

Latest news about Dian Diagnostics Group Co.,Ltd.

Dian Diagnostics Group Co.,Ltd. announces an Equity Buyback for CNY 200 million worth of its shares.	Feb. 06	CI
Dian Diagnostics Group Co.,Ltd. authorizes a Buyback Plan.	Feb. 05	CI
Dian Diagnostics Expands to Middle East With UAE Collaboration	Jan. 18	MT
Dian Diagnostics Group Co.,Ltd. Announces Executive Appointments	Nov. 06	CI
Dian Diagnostics Group Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-27	CI
Dian Diagnostics Group Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-30	CI
Dian Diagnostics Group Co.,Ltd. Announces Final Cash Dividend for A Shares, Payable on 31 May 2023	23-05-25	CI
Dian Diagnostics Group Co.,Ltd. Approves Cash Dividend for 2022	23-05-22	CI
Dian Diagnostics Group Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-26	CI
Dian Diagnostics Group Co.,Ltd. Announces the Profit Distribution Proposal for 2022	23-04-13	CI
Dian Diagnostics Group Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-12	CI
Geneus Tech announced that it has received funding from GF Xinde Investment Management Co., Ltd, Dian Diagnostics Group Co.,Ltd.	23-03-01	CI
Tranche Update on Dian Diagnostics Group Co.,Ltd.'s Equity Buyback Plan announced on December 7, 2022.	23-02-28	CI
Dian Diagnostics Group Co.,Ltd.'s Equity Buyback announced on December 7, 2022, has expired with 1,918,600 shares, representing 0.31% for CNY 49.99 million.	23-02-26	CI
Tranche Update on Dian Diagnostics Group Co.,Ltd.'s Equity Buyback Plan announced on December 7, 2022.	23-01-03	CI
Dian Diagnostics' Unit Plans to Buy Alta Scientific	22-12-23	CI
As China seeks to live with the virus, COVID-control industries face decline	22-12-15	RE
Dian Diagnostics Group Co.,Ltd. announces an Equity Buyback for CNY 50 million worth of its shares.	22-12-07	CI
Dian Diagnostics Group Co.,Ltd. authorizes a Buyback Plan.	22-12-06	CI
Chinese COVID testing firms report big profits as virus fight intensifies	22-11-03	RE
Dian Diagnostics Plans to Spin Off Unit for Listing	22-10-26	CI
Dian Diagnostics Group Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-26	CI
Dian Diagnostics Group Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-26	CI
Dian Diagnostics Group Co.,Ltd. Announces Final Cash Dividend on A Shares for 2021, Payable on 08 June 2022	22-06-01	CI
Zero-COVID, big money: China's anti-virus spending boosts medical, tech, construction	22-05-29	RE

Chart Dian Diagnostics Group Co.,Ltd.

Duration

Period

More charts

Dean Diagnostic Technology Group Co., Ltd. is a company providing integrated solutions for medical diagnosis. The Company's main business involves inspection services, product services, health management, judicial expertise, contract research organization (CRO), cold chain logistics and other fields. The Company's business is mainly oriented to medical and health institutions at all levels, such as various general and specialized hospitals, community health service centers, township (town) health centers, physical examination centers, disease prevention and control centers, etc. The Company's products include Atomic Bomb in the field of liquid phase mass spectrometry, Hydrogen Bomb in the field of nucleic acid mass spectrometry, and Man-Made Satellite in the field of pathological diagnosis products and molecular diagnosis products, and others.

Sector

Healthcare Facilities & Services

Calendar

2024-04-19 - Q4 2023 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Dian Diagnostics Group Co.,Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

14.99 CNY

Average target price

28.27 CNY

Spread / Average Target

+88.59%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical & Diagnostic Laboratories

	1st Jan change	Capi.
DIAN DIAGNOSTICS GROUP CO.,LTD.	-37.04%	1.29B
RADNET, INC.	+37.50%	3.52B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	-25.86%	3B
SYNLAB AG	-5.95%	2.53B
DR. LAL PATHLABS LIMITED	-9.80%	2.31B
NEOGENOMICS, INC.	-15.02%	1.76B
FLEURY S.A.	-20.62%	1.51B
METROPOLIS HEALTHCARE LIMITED	+5.93%	1.09B
ADICON HOLDINGS LIMITED	-9.36%	1.1B
H.U. GROUP HOLDINGS, INC.	-9.42%	893M

Medical & Diagnostic Laboratories